{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:10:14Z","timestamp":1785471014422,"version":"3.56.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01577-w","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T18:00:20Z","timestamp":1755885620000},"page":"1070-1085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Srikruthi Kunigal","family":"Sridhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasim Sakran","family":"Abass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buduru","family":"Gowthami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimbagal Raghavendra","family":"Naveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"1577_CR1","doi-asserted-by":"publisher","unstructured":"Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2(1):48\u201358. https:\/\/doi.org\/10.1038\/nrc706","DOI":"10.1038\/nrc706"},{"key":"1577_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0005-8","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD et al (2018) Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/s41568-018-0005-8","journal-title":"Nat Rev Cancer"},{"key":"1577_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.022","author":"A C\u00e9sar-Razquin","year":"2015","unstructured":"C\u00e9sar-Razquin A, Snijder B, Frappier-Brinton T et al (2015) A call for systematic research on solute carriers. Cell. https:\/\/doi.org\/10.1016\/j.cell.2015.07.022","journal-title":"Cell"},{"key":"1577_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrd4626","volume":"14","author":"L Lin","year":"2015","unstructured":"Lin L, Yee SW, Kim RB, Giacomini KM (2015) Slc transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov 14:543\u2013560","journal-title":"Nat Rev Drug Discov"},{"key":"1577_CR5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1517\/17425255.2012.722996","volume":"8","author":"AT Nies","year":"2012","unstructured":"Nies AT, Damme K, Schaeffeler E, Schwab M (2012) Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs. Expert Opin Drug Metab Toxicol 8:1565\u20131577","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1577_CR6","doi-asserted-by":"publisher","unstructured":"De Bruyn T, Van Westen GJP, IJzerman AP et al (2013) Structure-based identification of oatp1b1\/3 inhibitorss. Mol Pharmacol 83:1257\u20131267. https:\/\/doi.org\/10.1124\/mol.112.084152","DOI":"10.1124\/mol.112.084152"},{"key":"1577_CR7","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1172\/JCI30558","volume":"117","author":"Y Shu","year":"2007","unstructured":"Shu Y, Sheardown SA, Brown C et al (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422. https:\/\/doi.org\/10.1172\/JCI30558","journal-title":"J Clin Invest"},{"key":"1577_CR8","doi-asserted-by":"publisher","DOI":"10.1124\/mol.114.097451","author":"H Burger","year":"2015","unstructured":"Burger H, Den Dekker AT, Segeletz S et al (2015) Lysosomal sequestration determines intracellular imatinib levels. Mol Pharmacol. https:\/\/doi.org\/10.1124\/mol.114.097451","journal-title":"Mol Pharmacol"},{"key":"1577_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17425255.2020.1755253","volume":"16","author":"KM Huang","year":"2020","unstructured":"Huang KM, Uddin ME, DiGiacomo D et al (2020) Role of SLC transporters in toxicity induced by anticancer drugs. Expert Opin Drug Metab Toxicol 16:493\u2013506","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1577_CR10","doi-asserted-by":"crossref","unstructured":"Rives ML, Javitch JA, Wickenden AD (2017) Potentiating SLC transporter activity: emerging drug discovery opportunities. Biochem Pharmacol 135:1\u201311","DOI":"10.1016\/j.bcp.2017.02.010"},{"key":"1577_CR11","first-page":"293","volume":"9","author":"YD Bhutia","year":"2014","unstructured":"Bhutia YD, Babu E, Prasad PD, Ganapathy V (2014) The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy. Asian J Pharm Sci 9:293\u2013303","journal-title":"Asian J Pharm Sci"},{"key":"1577_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174375","author":"H Shindo","year":"2021","unstructured":"Shindo H, Harada-Shoji N, Ebata A et al (2021) Targeting amino acid metabolic reprogramming via L-type amino acid transporter 1 (Lat1) for endocrine-resistant breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13174375","journal-title":"Cancers (Basel)"},{"key":"1577_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2017.1344757","author":"NJ Clemons","year":"2017","unstructured":"Clemons NJ, Liu DS, Duong CP, Phillips WA (2017) Inhibiting system xC\u2212 and glutathione biosynthesis\u2013a potential achilles\u2019 heel in mutant-p53 cancers. Mol Cell Oncol. https:\/\/doi.org\/10.1080\/23723556.2017.1344757","journal-title":"Mol Cell Oncol"},{"key":"1577_CR14","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","volume":"176","author":"G Ciarimboli","year":"2010","unstructured":"Ciarimboli G, Deuster D, Knief A et al (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176:1169. https:\/\/doi.org\/10.2353\/ajpath.2010.090610","journal-title":"Am J Pathol"},{"key":"1577_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0769","author":"S Zhang","year":"2006","unstructured":"Zhang S, Lovejoy KS, Shima JE et al (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0769","journal-title":"Cancer Res"},{"key":"1577_CR16","doi-asserted-by":"crossref","unstructured":"Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26:153\u2013181","DOI":"10.1007\/s10555-007-9049-z"},{"key":"1577_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P et al (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697. https:\/\/doi.org\/10.1182\/blood-2005-11-4687","journal-title":"Blood"},{"key":"1577_CR18","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","volume":"19","author":"EI Zimmerman","year":"2013","unstructured":"Zimmerman EI, Hu S, Roberts JL et al (2013) Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 19:1458. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3306","journal-title":"Clin Cancer Res"},{"key":"1577_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000094541","volume":"70","author":"K Gloeckner-Hofmann","year":"2006","unstructured":"Gloeckner-Hofmann K, Guill\u00e9n-G\u00f3mez E, Schmidtgen C et al (2006) Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 70:238. https:\/\/doi.org\/10.1159\/000094541","journal-title":"Oncology"},{"key":"1577_CR20","doi-asserted-by":"publisher","first-page":"16473","DOI":"10.1074\/jbc.C000205200","volume":"275","author":"M Sugawara","year":"2000","unstructured":"Sugawara M, Nakanishi T, Fei YJ et al (2000) Cloning of an amino acid transporter with functional characteristics and tissue expression pattern identical to that of system A. J Biol Chem 275:16473. https:\/\/doi.org\/10.1074\/jbc.C000205200","journal-title":"J Biol Chem"},{"key":"1577_CR21","doi-asserted-by":"publisher","unstructured":"Hediger MA, Cl\u00e9men\u00e7on B, Burrier RE, Bruford EA (2013) The ABCs of membrane transporters in health and disease (SLC series): Introduction. Mol Aspects Med 34(2\u20133):95\u2013107. https:\/\/doi.org\/10.1016\/j.mam.2012.12.009","DOI":"10.1016\/j.mam.2012.12.009"},{"key":"1577_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-019-1011-z","volume":"568","author":"R Yan","year":"2019","unstructured":"Yan R, Zhao X, Lei J, Zhou Q (2019) Structure of the human LAT1\u20134F2hc heteromeric amino acid transporter complex. Nature 568:127. https:\/\/doi.org\/10.1038\/s41586-019-1011-z","journal-title":"Nature"},{"key":"1577_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2023.215431","volume":"496","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu J, Li W et al (2023) Responsive metal\u2013organic framework nanocarrier delivery system: an effective solution against bacterial infection. Coord Chem Rev 496:215431","journal-title":"Coord Chem Rev"},{"key":"1577_CR24","doi-asserted-by":"publisher","unstructured":"Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215\u2013236. https:\/\/doi.org\/10.1038\/nrd3028","DOI":"10.1038\/nrd3028"},{"key":"1577_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.mam.2012.10.007","volume":"34","author":"D Fotiadis","year":"2013","unstructured":"Fotiadis D, Kanai Y, Palac\u00edn M (2013) The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med 34:139\u2013158","journal-title":"Mol Aspects Med"},{"key":"1577_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2174\/157016109789043892","volume":"7","author":"M Molina-Arcas","year":"2009","unstructured":"Molina-Arcas M, Casado F, Pastor-Anglada M (2009) Nucleoside transporter proteins. Curr Vasc Pharmacol 7:426. https:\/\/doi.org\/10.2174\/157016109789043892","journal-title":"Curr Vasc Pharmacol"},{"key":"1577_CR27","doi-asserted-by":"publisher","unstructured":"Oda K, Hosoda N, Endo H et al (2010) L-Type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 101. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01386.x","DOI":"10.1111\/j.1349-7006.2009.01386.x"},{"key":"1577_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-018-0288-x","author":"P Koppula","year":"2018","unstructured":"Koppula P, Zhang Y, Zhuang L, Gan B (2018) Amino acid transporter SLC7A11\/ xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. https:\/\/doi.org\/10.1186\/s40880-018-0288-x","journal-title":"Cancer Commun"},{"key":"1577_CR29","doi-asserted-by":"publisher","unstructured":"Nies AT, Koepsell H, Damme K, Schwab M (2010) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Drug Transport 105\u2013167. https:\/\/doi.org\/10.1007\/978-3-642-14541-4_3","DOI":"10.1007\/978-3-642-14541-4_3"},{"key":"1577_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21933-6","author":"Z Jiang","year":"2018","unstructured":"Jiang Z, Dong X, Yan X et al (2018) Nanogels of dual inhibitor-modified hyaluronic acid function as a potent inhibitor of amyloid \u03b2-protein aggregation and cytotoxicity. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-018-21933-6","journal-title":"Sci Rep"},{"key":"1577_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115241","volume":"205","author":"J He","year":"2022","unstructured":"He J, Wang X, Chen K et al (2022) The amino acid transporter SLC7A11-mediated crosstalk implicated in cancer therapy and the tumor microenvironment. Biochem Pharmacol 205:115241","journal-title":"Biochem Pharmacol"},{"key":"1577_CR32","doi-asserted-by":"publisher","unstructured":"Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23(1):27\u201347.\nhttps:\/\/doi.org\/10.1016\/j.cmet.2015.12.006","DOI":"10.1016\/j.cmet.2015.12.006"},{"key":"1577_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.71","author":"BJ Altman","year":"2016","unstructured":"Altman BJ, Stine ZE, Dang CV (2016) From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/nrc.2016.71","journal-title":"Nat Rev Cancer"},{"key":"1577_CR34","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/onc.2015.381","volume":"35","author":"M Van Geldermalsen","year":"2016","unstructured":"Van Geldermalsen M, Wang Q, Nagarajah R et al (2016) ASCT2\/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene 35:3201. https:\/\/doi.org\/10.1038\/onc.2015.381","journal-title":"Oncogene"},{"key":"1577_CR35","doi-asserted-by":"crossref","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H et al (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171(2):273\u2013285","DOI":"10.1016\/j.cell.2017.09.021"},{"key":"1577_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.11.044","author":"P Nicklin","year":"2009","unstructured":"Nicklin P, Bergman P, Zhang B et al (2009) Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. https:\/\/doi.org\/10.1016\/j.cell.2008.11.044","journal-title":"Cell"},{"key":"1577_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020203","author":"C Lopes","year":"2021","unstructured":"Lopes C, Pereira C, Medeiros R (2021) ASCT2 and LAT1 contribution to the hallmarks of cancer: from a molecular perspective to clinical translation. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13020203","journal-title":"Cancers (Basel)"},{"key":"1577_CR38","doi-asserted-by":"crossref","unstructured":"Martinez-Outschoorn UE, Peiris-Pag\u00e9s M, Pestell RG et al (2017) Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 14(1):11\u201331","DOI":"10.1038\/nrclinonc.2016.60"},{"key":"1577_CR39","doi-asserted-by":"crossref","unstructured":"Br\u00f6er S (2014) The SLC38 family of sodium-amino acid co-transporters. Pflugers Arch Eur J Physiol 466:155\u2013172","DOI":"10.1007\/s00424-013-1393-y"},{"key":"1577_CR40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.mam.2012.05.005","volume":"34","author":"F Palmieri","year":"2013","unstructured":"Palmieri F (2013) The mitochondrial transporter family SLC25: identification, properties and physiopathology. Mol Aspects Med 34:465\u2013484","journal-title":"Mol Aspects Med"},{"key":"1577_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1124\/pr.118.015578","volume":"72","author":"H Koepsell","year":"2020","unstructured":"Koepsell H (2020) Organic cation transporters in health and disease. Pharmacol Rev 72:253. https:\/\/doi.org\/10.1124\/pr.118.015578","journal-title":"Pharmacol Rev"},{"issue":"3","key":"1577_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/17425255.2023.2202813","volume":"19","author":"MVS Varma","year":"2023","unstructured":"Varma MVS AQAQ (2023) Genetic variation in organic cation transporters and considerations in drug development. Expert Opin Drug Metab Toxicol 19(3):149\u2013164","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1577_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193021","author":"B Chhunchha","year":"2022","unstructured":"Chhunchha B, Kubo E, Singh DP (2022) Obligatory role of AMPK activation and antioxidant defense pathway in the regulatory effects of metformin on cellular protection and prevention of lens opacity. Cells. https:\/\/doi.org\/10.3390\/cells11193021","journal-title":"Cells"},{"key":"1577_CR44","doi-asserted-by":"publisher","unstructured":"Lin S, Zhang Q, Li S et al (2020) Antioxidative and angiogenesis-promoting effects of tetrahedral framework nucleic acids in diabetic wound healing with activation of the Akt\/Nrf2\/HO-1 pathway. ACS Appl Mater Interfaces 12. https:\/\/doi.org\/10.1021\/acsami.0c00874","DOI":"10.1021\/acsami.0c00874"},{"key":"1577_CR45","doi-asserted-by":"crossref","unstructured":"Hagenbuch B, Stieger B (2013) The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med 34(2\u20133):396\u2013412","DOI":"10.1016\/j.mam.2012.10.009"},{"key":"1577_CR46","doi-asserted-by":"publisher","unstructured":"Teft WA, Welch S, Lenehan J et al (2015) OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer 112. https:\/\/doi.org\/10.1038\/bjc.2015.5","DOI":"10.1038\/bjc.2015.5"},{"key":"1577_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.04.019","author":"T Farasyn","year":"2019","unstructured":"Farasyn T, Crowe A, Hatley O et al (2019) Preincubation with everolimus and sirolimus reduces organic anion-transporting polypeptide (OATP)1B1- and 1B3-mediated transport independently of mTOR kinase inhibition: implication in assessing OATP1B1- and OATP1B3-mediated drug-drug interactions. J Pharm Sci. https:\/\/doi.org\/10.1016\/j.xphs.2019.04.019","journal-title":"J Pharm Sci"},{"key":"1577_CR48","doi-asserted-by":"publisher","DOI":"10.1039\/D3TB00670K","author":"Z Wang","year":"2023","unstructured":"Wang Z, Chen T, Li X et al (2023) Oxygen-releasing biomaterials for regenerative medicine. J Mater Chem B. https:\/\/doi.org\/10.1039\/D3TB00670K","journal-title":"J Mater Chem B"},{"key":"1577_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.003","author":"A Ramachandran","year":"2013","unstructured":"Ramachandran A, Betts G, Bhana S et al (2013) An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.003","journal-title":"Eur J Cancer"},{"key":"1577_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/863539","author":"V Buxhofer-Ausch","year":"2013","unstructured":"Buxhofer-Ausch V, Secky L, Wlcek K et al (2013) Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv. https:\/\/doi.org\/10.1155\/2013\/863539","journal-title":"J Drug Deliv"},{"key":"1577_CR51","doi-asserted-by":"publisher","unstructured":"Yanagida O, Kanai Y, Chairoungdua A et al (2001) Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta - Biomembr 1514. https:\/\/doi.org\/10.1016\/S0005-2736(01)00384-4","DOI":"10.1016\/S0005-2736(01)00384-4"},{"key":"1577_CR52","doi-asserted-by":"publisher","unstructured":"Otani R, Takigawa H, Yuge R et al (2023) The anti-tumor effect of the newly developed LAT1 inhibitor JPH203 in colorectal carcinoma, according to a comprehensive analysis. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15051383","DOI":"10.3390\/cancers15051383"},{"key":"1577_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115103","volume":"201","author":"N Cappoli","year":"2022","unstructured":"Cappoli N, Jenkinson MD, Dello Russo C, Dickens D (2022) LAT1, a novel pharmacological target for the treatment of glioblastoma. Biochem Pharmacol 201:115103","journal-title":"Biochem Pharmacol"},{"key":"1577_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127976","volume":"254","author":"HH Wang","year":"2024","unstructured":"Wang HH, Fan SQ, Zhan YT et al (2024) Suppression of the SLC7A11\/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma. Int J Biol Macromol 254:127976. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.127976","journal-title":"Int J Biol Macromol"},{"key":"1577_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109874","volume":"78","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto M, Teramoto K, Katoh H (2021) Epidermal growth factor promotes glioblastoma cell death under glucose deprivation via upregulation of xCT (SLC7A11). Cell Signal 78:109874. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109874","journal-title":"Cell Signal"},{"key":"1577_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2005.06.002","author":"M Kirkham","year":"2005","unstructured":"Kirkham M, Parton RG (2005) Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta (BBA). https:\/\/doi.org\/10.1016\/j.bbamcr.2005.06.002","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"1577_CR57","doi-asserted-by":"crossref","unstructured":"Leyton JV (2020) Improving receptor-mediated intracellular access and accumulation of antibody therapeutics\u2014 the tale of her2. Antibodies 9:32","DOI":"10.3390\/antib9030032"},{"key":"1577_CR58","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10555-013-9441-9","volume":"32","author":"AS Azmi","year":"2013","unstructured":"Azmi AS, Bao B, Sarkar FH (2013) Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev 32:623\u2013642","journal-title":"Cancer Metastasis Rev"},{"key":"1577_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1445-x","author":"Y Wang","year":"2018","unstructured":"Wang Y, Liu KI, Sutrisnoh NAB et al (2018) Systematic evaluation of CRISPR-Cas systems reveals design principles for genome editing in human cells. Genome Biol. https:\/\/doi.org\/10.1186\/s13059-018-1445-x","journal-title":"Genome Biol"},{"key":"1577_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-019-09792-7","author":"SR Pillai","year":"2019","unstructured":"Pillai SR, Damaghi M, Marunaka Y et al (2019) Causes, consequences, and therapy of tumors acidosis. Cancer Metastasis Rev. https:\/\/doi.org\/10.1007\/s10555-019-09792-7","journal-title":"Cancer Metastasis Rev"},{"key":"1577_CR61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jcp.22400","volume":"226","author":"SK Parks","year":"2011","unstructured":"Parks SK, Chiche J, Pouyssegur J (2011) pH control mechanisms of tumor survival and growth. J Cell Physiol 226:299\u2013308","journal-title":"J Cell Physiol"},{"issue":"2","key":"1577_CR62","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1152\/physrev.00044.2016","volume":"98","author":"N Prevarskaya","year":"2018","unstructured":"Prevarskaya N, Skryma R, Shuba Y (2018) Ion channels in cancer: are cancer hallmarks oncochannelopathies? Physiol Rev 98(2):559\u2013621","journal-title":"Physiol Rev"},{"key":"1577_CR63","doi-asserted-by":"publisher","unstructured":"Jain RK (1997) Delivery of molecular and cellular medicine to solid tumors. Microcirculation 4(1):1\u201323.\u00a0https:\/\/doi.org\/10.3109\/10739689709148314","DOI":"10.3109\/10739689709148314"},{"key":"1577_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.04.018","volume":"154","author":"A Jetter","year":"2020","unstructured":"Jetter A, Kullak-Ublick GA (2020) Drugs and hepatic transporters: a review. Pharmacol Res 154:104234","journal-title":"Pharmacol Res"},{"key":"1577_CR65","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/jps.21851","volume":"99","author":"AI Alvarez","year":"2010","unstructured":"Alvarez AI, Real R, P\u00e9rez M et al (2010) Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 99:598\u2013617","journal-title":"J Pharm Sci"},{"key":"1577_CR66","doi-asserted-by":"publisher","DOI":"10.1593\/neo.11148","author":"R Rattan","year":"2011","unstructured":"Rattan R, Graham RP, Maguire JL et al (2011) Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. https:\/\/doi.org\/10.1593\/neo.11148","journal-title":"Neoplasia"},{"key":"1577_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114546","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhu Q, Hu H et al (2021) Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma. Biochem Pharmacol. https:\/\/doi.org\/10.1016\/j.bcp.2021.114546","journal-title":"Biochem Pharmacol"},{"key":"1577_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/molecules191016489","author":"A Dahan","year":"2014","unstructured":"Dahan A, Zimmermann EM, Ben-Shabat S (2014) Modern prodrug design for targeted oral drug delivery. Molecules. https:\/\/doi.org\/10.3390\/molecules191016489","journal-title":"Molecules"},{"key":"1577_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s12274-023-5568-3","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Cheng Q, Xue Y et al (2023) Lat1 targeted brain delivery of temozolomide and sorafenib for effective glioma therapy. Nano Res. https:\/\/doi.org\/10.1007\/s12274-023-5568-3","journal-title":"Nano Res"},{"key":"1577_CR70","doi-asserted-by":"publisher","unstructured":"Debbage P (2008) Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15. https:\/\/doi.org\/10.2174\/138161209787002870","DOI":"10.2174\/138161209787002870"},{"key":"1577_CR71","doi-asserted-by":"publisher","first-page":"594464","DOI":"10.3389\/fcell.2020.594464","volume":"8","author":"KA Na\u0142\u0119cz","year":"2020","unstructured":"Na\u0142\u0119cz KA (2020) Amino acid transporter SLC6A14 (ATB0,+) \u2013 a target in combined anti-cancer therapy. Front Cell Dev Biol 8:594464","journal-title":"Front Cell Dev Biol"},{"key":"1577_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708943","volume":"11","author":"NM Ayoub","year":"2021","unstructured":"Ayoub NM (2021) Editorial: Novel combination therapies for the treatment of solid cancers. Front Oncol 11:708943","journal-title":"Front Oncol"},{"key":"1577_CR73","doi-asserted-by":"publisher","unstructured":"Tang C, Kooburat T, Venkatachalam P, Chander A, Wen Z, Narayanan A, Dowell P, Karl R (2015) Holistic configuration management at facebook. In: Proceedings of the 25th symposium on operating systems principles\u00a0 Oct 4 (pp. 328\u2013343).\nhttps:\/\/doi.org\/10.1145\/2815400.2815401","DOI":"10.1145\/2815400.2815401"},{"issue":"2","key":"1577_CR74","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1021\/jacsau.2c00532","volume":"3","author":"Z Si","year":"2023","unstructured":"Si Z, Pethe K, Chan-Park MB (2023) Chemical basis of combination therapy to combat antibiotic resistance. JACS Au 3(2):276\u2013292","journal-title":"JACS Au"},{"key":"1577_CR75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/17425255.2022.2113380","volume":"18","author":"N Anabtawi","year":"2022","unstructured":"Anabtawi N, Drabison T, Hu S et al (2022) The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature. Expert Opin Drug Metab Toxicol 18:459\u2013468","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1577_CR76","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","volume":"38","author":"N Okano","year":"2020","unstructured":"Okano N, Naruge D, Kawai K et al (2020) First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs 38:1495. https:\/\/doi.org\/10.1007\/s10637-020-00924-3","journal-title":"Invest New Drugs"},{"key":"1577_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115681","volume":"214","author":"M Asensio","year":"2023","unstructured":"Asensio M, Herraez E, Macias RIR et al (2023) Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma. Biochem Pharmacol 214:115681. https:\/\/doi.org\/10.1016\/j.bcp.2023.115681","journal-title":"Biochem Pharmacol"},{"key":"1577_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53397-7","author":"K Higuchi","year":"2019","unstructured":"Higuchi K, Sakamoto S, Ando K et al (2019) Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-53397-7","journal-title":"Sci Rep"},{"key":"1577_CR79","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.123.001275","author":"T Fu","year":"2023","unstructured":"Fu T, Zeng S, Zheng Q, Zhu F (2023) The important role of transporter structures in drug disposition, efficacy, and toxicity. Drug Metab Dispos. https:\/\/doi.org\/10.1124\/dmd.123.001275","journal-title":"Drug Metab Dispos"},{"key":"1577_CR80","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.mam.2012.12.007","volume":"34","author":"S El-Gebali","year":"2013","unstructured":"El-Gebali S, Bentz S, Hediger MA, Anderle P (2013) Solute carriers (SLCs) in cancer. Mol Aspects Med 34:719\u2013734","journal-title":"Mol Aspects Med"},{"key":"1577_CR81","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1055\/s-0031-1296452","volume":"59","author":"K-L Hu","year":"2011","unstructured":"Hu K-L, Mei N, Feng L, Jiang X-G (2011) Hydrophilic nasal gel of lidocaine hydrochloride. Arzneimittelforschung 59:635. https:\/\/doi.org\/10.1055\/s-0031-1296452","journal-title":"Arzneimittelforschung"},{"key":"1577_CR82","doi-asserted-by":"crossref","unstructured":"Su H, Wang Y, Liu S et al (2019) Emerging transporter-targeted nanoparticulate drug delivery systems. Acta Pharm Sin B 9(1):49\u201358","DOI":"10.1016\/j.apsb.2018.10.005"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01577-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:04:08Z","timestamp":1760195048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01577-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01577-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The authors declare that Artificial Intelligence (AI) tools, including language models, were utilized solely for grammatical correction, sentence rephrasing, and language refinement during manuscript preparation. All scientific content, concepts, data analysis, and interpretations were generated and validated entirely by the authors without reliance on AI for content creation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of AI"}}]}}